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Background: Radiotherapy is an integral part of breast cancer treatment. Immune activating properties of especially
hypofractionated irradiation are in the spotlight of clinicians, besides the well-known effects of radiotherapy on cell
cycle and the reduction of the clonogenic potential of tumor cells. Especially combination of radiotherapy with
further immune stimulation induces immune-mediated anti-tumor responses. We therefore examined whether
hypofractionated irradiation alone or in combination with hyperthermia as immune stimulants is capable of
inducing breast cancer cells with immunogenic potential.
Methods: Clonogenic assay, AnnexinA5-FITC/Propidium iodide assay and ELISA analyses of heat shock protein 70 and
high mobility group box 1 protein were applied to characterize colony forming capability, cell death induction, cell
death forms and release of danger signals by breast cancer cells in response to hypofractionated radiation (4x4Gy,
6x3Gy) alone and in combination with hyperthermia (41.5 °C for 1 h). Caspase-3 deficient, hormone receptor positive,
p53 wild type MCF-7 and caspase-3 intact, hormone receptor negative, p53 mutated MDA-MB231 breast cancer cells,
the latter in absence or presence of the pan-caspase inhibitor zVAD-fmk, were used. Supernatants of the treated tumor
cells were analyzed for their potential to alter the surface expression of activation markers on human-monocyte-derived
dendritic cells.
Results: Irradiation reduced the clonogenicity of caspase deficient MCF-7 cells more than of MDA-B231 cells. In
contrast, higher amounts of apoptotic and necrotic cells were induced in MDA-B231 cells after single irradiation
with 4Gy, 10Gy, or 20Gy or after hypofractionated irradiation with 4x4Gy or 6x3Gy. MDA-B231 cells consecutively
released higher amounts of Hsp70 and HMGB1 after hypofractionated irradiation. However, only the release of
Hsp70 was further increased by hyperthermia. Both, apoptosis induction and release of the danger signals, was
dependent on caspase-3. Only supernatants of MDA-B231 cells after hypofractionated irradiation resulted in slight
changes of activation markers on dendritic cells; especially that of CD86 was upregulated and HT did not further
impact on it.
Conclusions: Hypofractionated irradiation is the main stimulus for cell death induction and consecutive dendritic
cell activation in caspase proficient breast cancer cells. For the assessment of radiosensitivity and immunological
effects of radio- and immunotherapies the readout system is crucial.* Correspondence: udo.gaipl@uk-erlangen.de
1Department of Radiation Oncology, University Hospital Erlangen,
Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Full list of author information is available at the end of the article
© 2015 Kötter et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kötter et al. Radiation Oncology  (2015) 10:197 Page 2 of 14Background
With approximately 70.000 new cases of disease per
year, breast cancer (mamma carcinoma) represents the
most frequent and, along with approximately 17.000
deaths per year, also the deadliest cancer disease for
women in Germany. One out of 8 German women will
suffer from mamma carcinoma during lifetime. This im-
plies that deep knowledge about breast cancer develop-
ment, mechanisms of tumor progression and related
treatments is mandatory. The main risk factors to de-
velop a mamma carcinoma are female gender and seni-
ority (>60 years). Breast cancer displays a heterogeneous
tumor disease and multiple subtypes exist [1]. Ductal,
originating from lactiferous ducts, are to be differed
from lobular carcinomas, originating from glandular
lobes. With about 70 % of the cases the invasive ductal
carcinoma is the prominent type [2]. Precancerous con-
ditions are the Ductal Carcinoma in situ (DCIS) and the
Carcinoma Lobulare in situ (CLIS), of which the DCIS
shows the more aggressive progress and in about a third
to half of the cases develops to an invasive carcinoma
within 10–20 years [3]. Benign and malignant pre-
existing conditions of the breast, genetic mutations,
most prominent in the BRCA (Breast Cancer) gene,
positive family history, long period of estrogen-exposure
(early menarche, late menopause, obesity) and life style
are main risk factors [4].
Triple negative breast cancer (TNBC) represents 15–20 %
of all breast cancers that lack estrogen receptor (ER)
and progesterone receptor (PgR) expression as well as
amplification of the human epidermal growth factor re-
ceptor 2 (HER2). TNBCs are an aggressive group of
breast cancers with higher rates of relapse and to date
not a single targeted therapy has been approved for its
treatment [5]. Combinational effects of chemotherapy,
photothermal therapy, and gene therapy with low drug
dose are currently tested as promising strategy for
TNBC treatment [6]. However, a relative radioresis-
tance for TNBC does not imply radiation omission,
because radiotherapy (RT) provides an absolute loco-
regional risk reduction [7].
RT is therefore a crucial component for the treatment
of breast cancer [8]. Commonly it is applied in daily frac-
tions of 1.8–2 Gy up to a total dose of 50 Gy [9]. However,
long term follow-up confirms that appropriately dosed
hypofractionated radiotherapy is safe and effective for pa-
tients with early breast cancer [10]. Meanwhile, the use of
fractions >2.0 Gy (hypofractionation) is standard in the
UK, and increasingly used internationally for this tumor
entity [11]. The results of the German multicenter phase
II trial (ARO-2010-01) also suggest that hypofractionation
with simultaneous integrated boost for early breast cancer
is feasible [12]. However, integration of RT in multimodal
breast cancer treatment still remains a challenge [13].Emerging evidence suggests that besides inducing local
DNA damage, RT promotes a pro-immunogenic milieu
within the tumor capable of stimulating host cancer-
specific immune responses. Immunogenic breast cancer
cell death stimulated by either high-dose RT alone or
concurrent chemoradiation regimens may contribute to
this [14]. Especially combination of RT with further
immune stimulation contributes to immune-mediated
abscopal effects of RT [15, 16]. Recent in vitro and
in vivo studies indicate a unique immune modulating
prospect of hyperthermia (HT), especially when com-
bined with RT [17].
Regional or local HT describes the overheating of cer-
tain body parts by using electromagnetic radiation, e.g.
microwaves. Temperatures of 40–44 °C for a period of at
least 60 min should be achieved for therapeutic effective-
ness [18]. Of note is that recommendations for the imple-
mentation of quality-assured hyperthermia treatments
should be followed when applying HT in multimodal ther-
apy settings [19]. A radiosensitizing effect of HT for the
treatment of breast cancer has been discussed for long
time [20, 21]. In the update of 2012 of the AGO Ger-
man interdisciplinary S3-guidelines for diagnostic, ther-
apy and follow-up care of breast cancer it is stated that
for chest wall recurrences, simultaneous chemotherapy
or hyperthermia as radiosensitizing methods may result
in higher response rates. For re-irradiation, combin-
ation of RT with HT received the Oxford Levels of
Evidence of 1b in these guidelines. A Meta-analysis of
23 studies with 1861 patients with tumors of the chest
wall, cervix, rectum, bladder, prostate, head-neck-region
and melanoma points out a highly significant benefit
regarding loco-regional tumor control when RT is com-
bined with HT [22].
Oldenborg and colleagues proposed and examined a
hypofractionated irradiation with a single dose of 4 Gy
or 3 Gy, respectively, twice a week plus HT for patients
with recurrent breast cancer in previously irradiated area
[23]. Of note is that no increasing toxicity was observed
when adding HT to RT for the treatment of high risk
breast carcinoma [24]. Re-irradiation in combination
with HT is an effective and a safe modality to treat loco-
regional recurrences of breast cancers [25]. Besides HT,
also electrochemotherapy is discussed to be beneficial
for chest wall breast cancer recurrence [26].
The dogma of classical radiobiology states that the cyto-
toxic effects of irradiation on tumor cells are due to induc-
tion of DNA double strand breaks. The colony forming
assay is used as gold standard to determine the “viability”
of cells as defined by bearing the capability to form col-
onies >50 cells. However, no predictions about cell death
of a single cell and forms of tumor cell death including
their immunogenicity can be drawn by this assay [27],
besides several other draw backs such as seeding the
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dependence of the treatment, disregarded cell-to-cell
communication, clump artifacts and unification of col-
onies of different sizes [28].
None repaired DNA damage can lead to cell death
via apoptosis, mitotic catastrophe, autophagy, or ter-
minal growth arrest senescence [29]. Defining life and
death is more problematic than one would guess and
regulated cell death often results in initiation of sec-
ondary regulated cell death accompanied by inflamma-
tory events [30]. The success of RT does therefore not
only derive from direct cytotoxic effects on the tumor
cells alone, but instead might also depend on resulting
innate as well as adaptive immune responses [31]. The
latter can be initiated by immunogenic cell death forms
such as necrosis (summarised in [32]).
While apoptotic cells when present in physiological
amounts exert non- or even anti-inflammatory effects
[33], primary and secondary necrotic cells lead to an ac-
tivation of the immune response by release of danger
signals such as high mobility group box protein 1
(HMGB1), Adenosine-Triphosphate (ATP) and/or heat
shock protein 70 (Hsp70) (summarised in [34]). Second-
ary necrotic cells derive from apoptotic ones that have
lost their membrane integrity during the course of cell
death execution [35]. Therefore they are also often
termed as late apoptotic cells. However, following the
definition of necrosis, namely the loss of membrane in-
tegrity, secondary necrosis is the better fitting term from
the immunological point of view.
Central in immune activation against the tumor by
therapy-induced immunogenic tumor cell death forms
are dendritic cells (DCs). High numbers of apoptotic
cells and danger signals released by primary and
secondary necrotic cells trigger maturation and activa-
tion of DCs [36, 37]. The latter then present tumor-
derived antigen to CD8+ T cells and thereby initiate
cytotoxic T cell responses against the tumor (sum-
marised in [38]).
Hence, based on the clinical launching of hypofrac-
tionated RT and addition of HT as radiosensitizer for
the treatment of breast cancer, our study opened the
question whether cell death forms and immunogenic
potential of breast cancer cells differs after hypofractio-
nated RT and/or HT. We focused on the MDA-MB231
breast cancer cell line representing triple-negative mes-
enchymal highly invasive human breast cancer cells and
MCF-7 breast cancer cells, being positive for ER and
PgR expression, but deficient for caspase-3, for com-
parison. As activation of caspases is widely considered
as the initiator mechanism of regulated cell death [30],
we especially focused on the role caspase-3 in induction
of cell death with immunogenic potential of breast can-
cer cells.Materials and methods
Cell culture
MCF-7 (ER positive; PgR positive; p53 wt; caspase-3 de-
ficient [39, 40]) representing luminal-epithelial weakly
invasive [41] and MDA-MB231 (ER negative; PgR nega-
tive; p53 mutated; caspase-3 intact) [42] representing
triple-negative mesenchymal highly invasive [41] human
breast cancer cells were grown in Dulbecco’s modified
eagle medium (DMEM, PAN-Biotech, Germany) at
37 °C, 5 % CO2 and 90 % humidity to 70-80 % confluence.
10 % fetal bovine serum (FBS superior, Biochrom,
Germany) and 0,4 μl/ml Gentamicin were added to
optimize the growing situation. Both cell lines were ob-
tained from the American Type Culture Collection
(ATCC, Germany) and tested to be free of mycoplasma
contamination.
Treatment of the tumor cells with ionizing irradiation
and/or hyperthermia
Irradiation of the cells was performed with an X-ray gen-
erator (120 kV, 22.7 mA, variable time; GE Inspection
Technologies, Hürth, Germany). A dose of 2, 4, 10 or
20Gy was applied for irradiation with a single dose and
4x4Gy or 6x3Gy for the fractionated treatments. The
latter treatment schemes should mimic in our preclinical
in vitro model system clinically relevant hypofractionated
irradiation schemes as proposed by Oldenborg and
colleagues: single fractions of 4Gy (8 times; two fractions a
week) or of 3Gy (12 times; two fractions a week) [23].
Hyperthermia (HT) at 41.5 °C for 1 h was applied 4 h be-
fore or after irradiation, mimicking the time window of
combined application of RT and HT in the clinics [43].
For HT treatment, a HT-chamber constructed by our
physicists was used [44]. Fractionated irradiation was
combined with HT on the first and last day of the distinct
fractionation scheme. To block caspases in caspase 3 pro-
ficient MDA-MB231 cells, the pan-caspase inhibitor
zVAD-fmk was added to the cell cultures in a concentra-
tion of 50 μM at day one and three or four during hypo-
fractionated irradiation with 4x4Gy or 6x3Gy, respectively.
Colony formation assay
The descent of proliferation competent and therefore
colony forming tumor cells after the respective treat-
ments was assessed with clonogenic assays. For this,
the cells were plated in triplicates in 60-mm dishes
(Nunc Thermo Fisher, Waltham, USA) at concentra-
tions estimated to yield 40–150 colonies/dish. After-
wards, the cells were treated with a single dose
irradiation of 1, 2, 4, 6, 8, or 10Gy with or without
hyperthermia 4 h before or after the irradiation. After
incubation for approximately two weeks, the cells were
fixed with methylene blue (Sigma-Aldrich, Munich,
Germany) for 30 min. Colonies with >50 cells were
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ratic fitting curves upon the colony forming assays was
performed with the R package ‘CFAssay’ (version 1.2.0.)
on R 3.2.1 [45].Analyses of cell death forms and cell cycle phases with
flow cytometry
To identify different forms of tumor cell death, the expos-
ure of phosphatidylserine on the surface of apoptotic cells
was analyzed using FITC-labeled AnnexinV (AnxA5-FITC).
To distinguish apoptotic cells from necrotic ones, the co-
staining with propidium iodide (PI) was applied as
described by Koopman et al. [46]. Apoptotic cells are re-
ferred to as being positive for AnxA5 binding and negative
for PI intercalation into the DNA, and necrotic ones are
positive for both, AnxA5 and PI binding. Necrotic ones
can be further distinguished in primary necrotic ones with
a DNA content of viable cells (PI++) and secondary nec-
rotic/late apoptotic ones with already reduced DNA con-
tent (PI+) due to preceding apoptotic blebbing. However,
from the immunological points of view, cells which stain
positive for AnxA5 and PI are those that have lost their
membrane integrity, are necrotics and therefore bear
higher immunogenic potential. For analysis of cell death
and its main forms, 1 x 105 cells were transferred in 400 μl
of Ringer’s solution (B. Braun, Melsungen, Germany)
containing 0.2 μg AnxA5-FITC and 0.4 μg PI. After 30 min
of incubation at 4 °C in the dark, the samples were ana-
lyzed by flow cytometry. AnxA5 protein was expressed
and produced in 293 human embryonic kidney cells (Free-
Style™ 293 Expression System) and purified (life technolo-
gies, GENEART, Regensburg, Germany). Labelling with
FITC was performed with the FluoroTag™ FITC Conjuga-
tion Kit (Sigma Aldrich, St. Louis, MO, USA) according to
the manufacturer’s instructions.
Since the amount of DNA differs between the phases in
the cell cycle, a staining of it with PI in the presence of de-
tergent (to allow PI to pass the cell membrane) can be
used to analyze the cell cycle phases [47]. Cells in the G2
phase of the cell cycle have a doubled DNA content com-
pared to those in the G1 phase. Degraded DNA (subG1
DNA content of a cell) can also be analyzed by this
method, identifying late apoptotic/secondary necrotic
cells that already have exported degraded DNA via
apoptotic blebs [35]. In brief, cells (5 × 105) were fixed
at least for 20 min in 70 % ethanol at −20 °C. After
permeabilization of cells with TritonX-100 containing
solution, cells were incubated for 30 min with 200 μg/
ml RNase A (Roche, Mannheim, Germany) and 5 μg/ml
PI at room temperature. An EPICS XL MCL (Beckman
Coulter, USA) flow cytometer was utilized for both, cell
death and cell cycle analyses.Detection of the danger signal Hsp70 and of HMGB1
Heat shock proteins are a set of proteins performing
different tasks depending on their location. Inside cells
they act as chaperones helping in correct protein-
folding, especially preventing dangerous misfolded inter-
mediates being built during cell stress situations. When
released from cells, they can act as danger signals such
as HMGB1 and are potent stimulators of the adaptive
and innate immune system [48]. For detection and
quantification of Hsp70 in supernatants of tumor cells
the enzyme-linked-immunosorbent assay (ELISA) Duo-
Set IC Kit (R&D Systems, USA) was used according to
the manufacturer’s instructions. HMGB1 was quantified
with the ELISA of Shino-Test Corporation (Kanagawa,
Japan) also according to the manufacturer’s instructions.Differentiation, maturation and activation of human
dendritic cells (DCs)
Peripheral blood mononuclear cells (PBMCs) were ob-
tained from human leukocyte cones (ethical approval Nr.
180_13B of IMMO-TuKo-01) using Ficoll-gradient in-
duced blood fragmentation. Therefore the content of a 10 ml
leukocyte cone, repeatedly washed with in total 40 ml
PBS, was added to four Greiner blue cap centrifuge tubes
(Sigma-Aldrich, Germany) containing 12,5 ml Lymphoflot
(Bio-rad, Germany) and centrifuged for 20 min at 850 x g.
Afterwards the PBMCs, building a proper layer, could eas-
ily be separated. The gathered PBMCs were washed
three times with 4 °C cold PBS-EDTA (1 ml 0,5 molar
PH 7,5 EDTA on 500 ml PBS) and one time with
Roswell Park Memorial Institute (RPMI) medium
(Lonza, Switzerland) before being seeded out in a con-
centration of 3,5 x 107 PBMCs per 10 ml RPMI
medium refined with 1 % heat inactivated, 0,22 μm fil-
tered human plasma (Sigma, USA), 1 % L-Glutamine
(Gibco, United Kingdom) and 0,4 μl/ml Gentamicin
(Gibco, United Kingdom) on 100 mm x 20 mm BD
Falcon Tissue Culture Dishes (BD Biosciences, USA).
PBMCs were differentiated to DCs by adding 250 U
IL4 (PeproTech, Rocky Hill, NJ) and 800 U GM-CSF
(PeproTech, Rocky Hill, NJ) per mL medium on day 1, 3
and 5 after isolation according to the protocol of Sallusto
et al. [49]. On day 6, the cells were incubated with
10 ml supernatant of approximately 5 x 105 treated
tumor cells. 48 h afterwards, the surface expression of
different DC activation markers was analyzed using
fluorescence labeled antibodies (CD25-FITC (Beckman
Coulter, France) , CD40-PerCP/Cy5.5 (Biolegend, USA),
CD70-PE (BD Biosciences, USA), CD80-PC7 (Biole-
gend, USA) , CD83-PE (BD Biosciences, USA), CD86-
PerCP/Cy5.5 (Biolegend, USA), DC-SIGN-APC (eBio
science, USA), HLA-DR-Pacific blue (Beckman Coulter,
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Gallios flow cytometer (Beckman Coulter, USA).
Statistical analysis
Data were expressed as the mean ± standard deviation
(SD) and analyzed for statistical significance using Stu-
dents t-test (two-tailed) and that for danger signal
release by Two-Way ANOVA test. A p value <0.05 was
considered to be significant and one of <0.01 as highly
significant. Comparison of linear-quadratic cell survival
curves was performed by an F-Test calculated with the R
package ‘CFAssay’ (version 1.2.0.) on R 3.2.1 [45].
Results
Irradiation reduces the colony formation of caspase-3
deficient MCF-7 to a greater extent than in caspase-3
proficient MDA-MB231 cells
MDA-MB231 cells are more resistant to radiation as
MCF-7 cells when regarding the colony formation cap-
ability (Fig. 1a). However, MDA-MB231 cells respond
slightly better to addition of HT to irradiation than
MCF-7 cells (Fig. 1b), since the surviving fraction was
significantly further reduced when adding HT before or
after irradiation (RT) (Fig. 1c).
MCF-7 cells are resistant to cell death induction by
irradiation
In contrast to the reduced clonogenicity of MCF-7 cells
after RT, but corresponding to deficiency of caspase-3,
MCF-7 cells are resistant to cell death induction by RT,
HT and combined treatments (Fig. 2a). Not earlier than
72 h after treatment, only a slight increase of apoptotic
and necrotic MCF-7 cells was observed, starting at an ir-
radiation dose of 4Gy (Fig. 2b). Of note is that HT ap-
plied before (Fig. 2) or after (not shown) RT did not
impact on the percentage of apoptotic and necrotic
MCF-7 cells.
Radiation induces a mixture of apoptotic and necrotic
MDA-MB231 cells
In contrast to MCF-7 cells, caspase-3 proficient MDA-
MB231 (Fig. 3) cells underwent apoptotic and necrotic
cell death already 24 h after irradiation with 4Gy or
higher doses (Fig. 3a). A mixture of apoptotic and nec-
rotic tumor cells was induced, while necrosis slightly
dominated over apoptosis. HT did not significantly im-
pact on cell death induction of MDA-MB231 by RT.
Three days after the treatments, apoptotic MDA-MB231
cells dominated over necrotic ones and a high percent-
age of apoptotic cells was induced by RT, again starting
at a single radiation dose of 4Gy (Fig. 3b).
Hence especially hypofractionated RT should be promis-
ing with regard to cell death induction of breast cancer
cells. We therefore focused in the subsequent experiments
Fig. 1 Colony formation of MCF-7 and MDA-MB231 breast cancer
cells after irradiation and/or hyperthermia. MCF-7 (a, b) or MDA-MB231
(a, c) tumor cells were irradiated with ionizing radiation (IR)
and/or treated with hyperthermia (41,5 °C for 1 h). The cells were
irradiated 4 h before or after HT treatment. The dose-dependent
clonogenic potential (surviving fraction) was determined after 2 weeks
of incubation. Representative data of one out of three experiments,
each performed in triplicates, are presented as mean ± SD. Gy: Gray;
HT: hyperthermia; w/o: mock treated control. + p <0,05, ++ p <0,01;
§ p <0,05, §§p <0,01 HT + RT compared to RT only treated; ^ p <0,05,
^^ p <0,01 RT + HT compared to RT only treated
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been also proposed for RT treatment of recurrent breast
cancer in combination with HT by Oldenborg et al. [23].Hypofractionated RT induces apoptosis and necrosis of
MDA-MB231 cells
As already observed for irradiation with a single dose,
MDA-MB231 cells underwent apoptosis and necrosis
also after hypofractionated irradiation with 4x4Gy or
6x3Gy, already 24 h after the last treatment (Fig. 4b).
Adding HT to RT resulted in a slight increase of
apoptotic MDA-MB231 cells. The latter are most
likely late apoptotic ones with still intact membrane
integrity, since a significant increase of MDA-MB231
with subG1 DNA content was also observed when
adding HT to hypofractionated RT (Fig. 4d). Hypo-
fractionated RT in general induced a high percentage
of MDA-MB231 cells with subG1 DNA content
(Fig. 4d), while only few MCF-7 cells (<5 %) had
already degraded DNA (Fig. 4c). In general, fraction-
ated RT induced only low percentages of necrotic and
apoptotic MCF-7 cells (Fig. 4a).Fig. 2 Forms of MCF-7 breast cancer cell death after irradiation and/or hyp
of ionizing radiation and/or treated with hyperthermia (41,5 °C for 1 h). The
the last treatment, the cells were stained with AnxA5-FITC/PI and cell death w
+/PI-) and necrotic (AnxA5+/PI+ and PI++) tumor cells are displayed. Rep
triplicates, are presented as mean ± SD. Gy: Gray; HT: hyperthermia; w/o:Hypofractionated RT especially in combination with HT
induces the release of Hsp70 by MDA-MB231, but not by
MCF-7 cells
Concomitant with the low cell death induction by frac-
tionated RT and/or HT in MCF-7 cells, no significant in-
creased concentrations of the danger signal Hsp70 were
observed in the supernatants of the tumor cells after the
respective treatments (Fig. 5a). However, again in MDA-
MB231 cells, along with the high percentage of cells
with subG1 DNA content (Fig. 4d), especially hypofrac-
tionated RT in combination with HT induced the release
of Hsp70 in the tumor cells supernatant (Fig. 5b).
Radiation-induced apoptosis and secondary necrosis of
MDA-MB231 cells is dependent on caspase-3
To test whether the deficiency of caspase-3 in MCF-7
cells is the main reason for the lower response regarding
cell death induction compared to MDA-MB231 cells,
the pan-caspase inhibitor zVAD-fmk was added to
MDA-MB231 cells twice during hypofractionated irradi-
ation. As shown in Fig. 6, the addition of zVAD-fmk re-
sulted in significant reduced percentages of apoptotic
and secondary necrotic MDA-MB231 cells under all ir-
radiation conditions.
MDA-MB231 release low amounts of HMGB1 after
hypofractionated RT which is dependent on caspase-3 as
the Hsp70 release
While the danger signal HMGB1 was not detected in su-
pernatants of MCF-7 cells (not shown), low concentrations
(below 20 ng/ml) were detectable after hypofractionated ir-
radiation (Fig. 7a). Blocking apoptosis and consecutive
secondary necrosis in MDA-MB231 by zVAD-fmk de-
creased HMGB1 in the supernatants of the tumor cells.erthermia. MCF-7 breast cancer cells were irradiated with single doses
cells were irradiated 4 h after HT treatment. 24 h (a) or 72 h (b) after
as analyzed by flow cytometry. The percentages of apoptotic (AnxA5
resentative data of one out of two experiments, each performed in
mock treated control. *p <0,05, **p <0,01 related to w/o
Fig. 3 Forms of MDA-MB231 breast cancer cell death after irradiation and/or hyperthermia. MDA-MB231 breast cancer cells were irradiated with single
doses of ionizing radiation and/or treated with hyperthermia (41,5 °C for 1 h). The cells were irradiated 4 h after HT treatment. 24 h (a) or 72 h (b) after
the last treatment, the cells were stained with AnxA5-FITC/PI and cell death was analyzed by flow cytometry. The percentages of apoptotic (AnxA5
+/PI-) and necrotic (AnxA5+/PI+ and PI++) tumor cells are displayed. Representative data of one out of two experiments, each performed in
triplicates, are presented as mean ± SD. Gy: Gray; HT: hyperthermia; w/o: mock treated control. *p <0,05, **p <0,01 related to w/o
Fig. 4 Forms of MCF-7 and MDA-MB231 breast cancer cell death after hypofractionated irradiation and/or hyperthermia. MCF-7 (a, c) or MDA-MB231
(b, d) breast cancer cells were treated with hypofractionated irradiation (4x4Gy or 6x3Gy) and/or hyperthermia (41,5 °C for 1 h). Ionizing irradiation was
applied 4 h before or after hyperthermia on the first and last day of fractionation. 24 h after the last treatment, the cells were harvested. The cells were
then stained with AnxA5-FITC/PI and cell death was analyzed by flow cytometry. The percentages of apoptotic (AnxA5+/PI-) and necrotic (AnxA5+/PI+
and PI++) tumor cells are displayed in (a and b). For determination of the DNA content, the cells were stained with PI in the presence of
detergent and also analyzed by flow cytometry. The percentage of cells with subG1 DNA-content is displayed in (c and d). Representative
data of one out of three experiments, each performed in triplicates, are presented as mean ± SD. Gy: Gray; HT: hyperthermia; w/o: mock
treated control. *p <0,05, **p <0,01 compared to w/o; #p <0,05, ##p <0,01 related to only irradiated samples
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Fig. 5 Hsp70 release of MCF-7 and MDA-MB231 breast cancer cells after hypofractionated irradiation and/or hyperthermia. MCF-7 (a) or MDA-
MB231 (b) breast cancer cells were treated with hypofractionated irradiation (4x4Gy or 6x3Gy) and/or hyperthermia (41,5 °C for 1 h). Ionizing
irradiation was applied 4 h before or after hyperthermia on the first and last day of fractionation. 24 h after the last treatment, supernatants were
analyzed for the amount of extracellular heat shock protein 70. Representative data of one out of four experiments, each performed at least in
triplicates, are presented as mean ± SD. Gy: Gray; HT: hyperthermia; Hsp70: heat shock protein 70; w/o: mock treated control. *p <0,05, **p <0,01
compared to w/o; #p <0,05, ##p <0,01 compared to irradiated samples; +p <0,05, ++p <0,01 comparing 4x4Gy vs 6x3Gy treatments
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zVAD-fmk to the cell cultures significantly reduced the
radiation- and radiation plus HT-induced Hsp70 release
(Fig. 7b).
Hypofractionated RT of MDA-MB231 but not of MCF-7
cells creates tumor cell supernatants that slightly increase
the expression of activation markers on dendritic cells
After co-incubation for two days of human monocyte-
derived DCs with supernatants (SNs) of MCF-7 cells, no
significant changes in the surface expression of activa-
tion markers on DCs could be observed when compar-
ing SNs of untreated (w/o) or RT and/or HT treatedFig. 6 Impact of caspase inhibition on forms of MDA-MB231 breast cancer
MDA-MB231 breast cancer cells were treated with hypofractionated irradiation (
inhibitor zVAD-fmk was added to the cell cultures in a concentration of 50 μM
with 4x4Gy or 6x3Gy, respectively. Ionizing irradiation was applied 4 h before
the last treatment, the cells were harvested. The cells were then stained wit
percentages of apoptotic (AnxA5+/PI-), secondary necrotic (AnxA5+/PI+) and
data of one out of two experiments, each performed in triplicates, are presen
zVAD: pan caspase inhibitor zVAD-fmk. *p <0,05, **p <0,01 compared to sampcells (Fig. 8a1 and a2). Of note is that the untreated
MCF-7 cells are per se more immunogenic compared
to MDA-MB231 cells (Fig. 8). However, SNs of irradi-
ated MDA-MB231 cells with lower basal immunogenicity
induced a significant increased surface expression of the
activation markers CD80 and especially of CD86 on
DCs (Fig. 8b1 and b2). Concomitantly, the surface ex-
pression of DC-SIGN was significantly reduced, also a
clue for the activation of DCs. A slight, but not sig-
nificant increase of the DC homing receptor CCR7
which was generally very low expressed was also seen
after incubation of DCs with supernatants of MDA-
MB231 cells that had been treated with hypofractionatedcell death after hypofractionated irradiation and/or hyperthermia.
4x4Gy or 6x3Gy) and/or hyperthermia (41,5 °C for 1 h). The pan-caspase
at day one and three or four during hypofractionated irradiation
or after hyperthermia on the first and last day of fractionation. 24 h after
h AnxA5-FITC/PI and cell death was analyzed by flow cytometry. The
primary necrotic (AnxA5+/PI++) tumor cells are displayed. Representative
ted as mean ± SD. Gy: Gray; HT: hyperthermia; w/o: mock treated control;
les without zVAD
Fig. 7 Impact of caspase inhibition on HMGB1 and Hsp70 release by MDA-MB231 breast cancer cells after hypofractionated irradiation and/or
hyperthermia. MDA-MB231 breast cancer cells were treated with hypofractionated irradiation (4x4Gy or 6x3Gy) and/or hyperthermia (41,5 °C for 1 h).
Ionizing irradiation was applied 4 h before or after hyperthermia on the first and last day of fractionation. The pan-caspase inhibitor zVAD-fmk was
added to the cell cultures in a concentration of 50 μM at day one and three or four during hypofractionated irradiation with 4x4Gy or
6x3Gy, respectively. 24 h after the last treatment, supernatants were analyzed for the amount of extracellular HMGB1 (a) and Hsp 70 (b).
Representative data of one out of two experiments, each performed at least in triplicates, are presented as mean ± SD. Gy: Gray; HT:
hyperthermia; HMGB1: high mobility group box protein 1; Hsp70: heat shock protein 70; n.d.: not detectable; w/o: mock treated control;
zVAD: pan caspase inhibitor zVAD-fmk. **p <0,01 compared to samples without zVAD
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on the expression of activation markers on DCs (Fig. 8).
Discussion
Although the last decades brought a wide enlargement
of breast cancer therapies, there are still several limita-
tions which need to be vanquished [50]. Advances in
chemo- and radiotherapy, surgical techniques and the
development of new targeted agents have significantly
improved clinical outcomes for patients with locally ad-
vanced breast cancer [51]. Radiotherapy is an integral
part of the therapy for local tumor control and we ob-
served that the triple negative but caspase 3 proficient
MDA-MB231 cells are less radiosensitive than the MCF7
cells regarding the clonogenicity (Fig. 1). However, higheramounts of apoptotic and necrotic cells are induced by ir-
radiation starting at 4Gy in MDA-MB231 cells compared
to MCF-7 cells (Fig. 2). This highlights that definition of
“radiosensitivity” is diverse in dependence of the focus on
tumor cells clonogenicity or cell death, respectively, and
that cell death is dispensable for radiation-induced reduc-
tion of clonogenicity [27, 52]. Along the same line, while
HT did not impact on cell death induction (Fig. 3), it
slightly, but significantly reduced the surviving fraction
based on the clonogenicity of MDA-MB231 cells (Fig. 1c).
Further, addition of HT to hypofractionated RT reduced
the amount of cells in the radiosensitive G2 cell cycle
phase only in MDA-MB231 slightly, but significantly
(Additional file 1: Figures S1). This could indicate that p53
mutated tumor cells such as MDA-MB231 response to
Fig. 8 Surface expression of activation markers by dendritic cells after contact with supernatants of MCF-7 or MDA-MB231 breast cancer cells. The
surface expression of CD80, CD86, and DC-SIGN on DCs was analyzed by flow cytometry (representative primary data are displayed in a1 and b1) after
incubation for two days of immature DCs with cell culture supernatants of MCF-7 (a) or MDA-MB231 (b) tumor cells treated with hypofractionated
irradiation (4x4Gy or 6x3Gy) and/or hyperthermia (41,5 °C for 1 h). Ionizing irradiation was applied 4 h before or after hyperthermia on the first and last
day of fractionation. Representative data of one out of three experiments, each performed in triplicates, are presented as mean ± SD in a2 for MCF-7
cells and b2 for MDA-MB231 cells. DCs: dendritic cells; Gy: Gray; HT: hyperthermia; MFI: mean fluorescence intensity; w/o: mock treated control; neg:
immature DCs in medium only; pos: immature DCs incubated with IL-1β, PGE2, IL-6 and TNFα instead of tumor cell supernatants; *p <0,05, **p <0,01
compared to w/o
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observed for checkpoint kinase inhibitors [53].
While for the aggressive triple-negative breast cancer
subtype innovative treatment methods based mainly on
chemotherapy, biologic agents and radiotherapy show
also good tumor control, a limited time of disease free
survival is still the reality [54]. This implies that especially
systemic immune activation might be beneficial for fight-
ing metastases and recurrent tumors [38]. For activation
of the immune system the endoplasmatic reticulum (ER)stress and forms of tumor cell death are decisive and not
the clonogenicity of the tumor cells themselves [55, 56].
Hypofractionated irradiation was used in our preclinical
in vitro assays, since 10 years follow-up confirmed that
hypofractionated RT is safe and effective for patients with
early breast cancer [10]. In preclinical model systems,
abscopal and immune mediated effects in breast cancer
are mainly observed when combining hypofractionated ir-
radiation with further immune stimulation [57]. We fo-
cused on hyperthermia as a promising enhancer of RT
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stimulator of the immune system by generating an in situ
tumor vaccine [17]. Here, DCs are central since they link
innate and adaptive immune responses and are stimula-
tors of CD8+ cytotoxic T cell responses. Such tumor infil-
trating lymphocytes (TILs) have been demonstrated to
predict higher pathologic complete response rates in triple
negative patients [58, 59].
Our data suggest that caspase-3 proficient MDA-
MB231 can be rendered more immunogenic by hypo-
fractionated irradiation. Treatment of these cells with
ionizing radiation resulted in a mixture of apoptotic and
necrotic cells at doses of 4Gy and above (Fig. 3a and b).
This mixture of dying and dead tumor cells is supposed
to bear a high immunogenic potential [60]. When
MDA-MB231 cells were treated with 4x4Gy or 6x3Gy
hypofractionated irradiation, also a mixture of apoptotic
and necrotic cells resulted (Figs. 4 and 6). HT did impact
on the percentage of cells with subG1 content (Fig. 4d)
and the release of the danger signal Hsp70 (Figs. 5b and
7b): both were increased when HT was added to hypo-
fractionated RT in MDA-MB231 cells.
In MCF-7 cells, cell death induction by RT was much
weaker and HT did not increase the amount of late
apoptotic cells with increased subG1 DNA content nor
resulted in release of Hsp70 or HMGB1. This could sug-
gest that especially combination of hypofractionated RT
with HT in caspase-3 proficient cells such as MDA-
MB231 cells generates tumor cell SNs that lead to
increased expression of activation markers on DCs.
However, the expression of the CD80 and CD86 on
DCs was increased when incubating immature DCs
with SNs of MDA-MB231 cells that had been exposed
to hypofractionated irradiation. Addition of HT did not
significantly impact on it (Fig. 8b). Concomitantly, a de-
creased expression of DC-SIGN was detected. Since
ligation of DC-SIGN on DCs actively primes DCs to in-
duce Tregs, a reduced expression is favorable for induc-
tion of anti-tumor immune responses [61]. Regarding
the homing receptor CCR7 on DCs, also a slight, but
not significant, increased expression was observed after
hypofractionated RT (not shown). This is favorable for
directing the DCs to the next lymph nodes where they
then prime naïve T cells [62]. We have previously
shown that the SNs of colorectal tumor cells that had
been treated with RT plus HT also induce a significant
up-regulation of expression of CD80 and CCR7 on DCs
and that Hsp70 is one mediator of it. However, Hsp70
is not the sole stimulus for this, since HT treatment
alone resulted in a comparable release of Hsp70 com-
pared to RT plus HT, while only a very slight increase
of expression of CD 80 and CCR-7 on DCs was ob-
served in the case of only HT application [44]. In the
case of the MDA-MB231 breast cancer cells, slightlyhigher concentrations of Hsp70 in tumor cell SNs after
combination of fractionated RT with HT is not the key
stimulus for increased surface expression of activation
markers on DCs (Fig. 8). This necessitates that further
immune stimulatory molecules besides Hsp70s, which
have to be identified in future work, are released by the
breast cancer cells. HMGB1 might be one component
of it, since its concentration is slightly increased in
MDA-B231 cells, but not in MCF-7 cells, only in de-
pendence of irradiation (Fig. 7a). The increased amount
of Hsp70 after combination of hypofractionated RT
with HT might rather lead to activation of NK cells
than to further stimulate DCs [63, 64].
Caspases are central for most apoptosis inductions [65].
We proved that apoptosis and consecutive secondary
necrosis-induction by hypofractionated irradiation of
breast cancer cells is dependent on caspase-3 and can
therefore be efficiently blocked by the pan-caspase inhibi-
tor zVAD-fmk (Fig. 6). We conclude that hypofractionated
RT induces cell death only in caspase-3-proficient breast
cancer cells. Addition of HT to hypofractionated RT fos-
ters the release of Hsp70 by these cells, but does not gen-
erate tumor cell SNs that do further increase the
hypofractionated radiation-dependent enhanced expres-
sion of activation markers on DCs (Fig. 8).
We conclude that, in the light of personalized
medicine, for the assessment of radiosensitivity and
local as well as expected systemic cancer treatment
efficacy of distinct fractionation schemes of radiation
and additional immunotherapies for breast cancer, the
readout system is crucial and has to be announced
stringently. As demonstrated, clonogenicity is not pri-
marily linked to caspases: caspase deficient MCF-7
cells are reduced in their clonogenic potential more
than MDA-B231 cells. However, an additional stimu-
lus such as HT might differentially impact on it, since
only in MDA-B231 cells the clonogenic potential was
further reduced by adding HT to irradiation. Cell
death induction and distinct forms of cell death on
the contrary reflect the killing efficacy of treatments
and is connected to caspase integrity: Higher amounts
of apoptotic and necrotic cells are induced in MDA-
B231 cells by especially irradiation. To gain first hints
about the immunogenic potential of the cancer cells,
analyses of released danger signals should be per-
formed. MDA-B231 cells released higher amounts of
Hsp70 and HMGB1 after fractionated RT. However,
only the release of Hsp70 was further increased by
HT. Further, continued testing as incubation of the
SNs with DCs is necessary. Our data revealed that
HT did not further increase the hypofractionated
radiation-dependent enhanced expression of activation
markers on DCs. Finally, upregulation of activation
markers on DC might also result in tolerance, so
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increasingly performed in the future.
Nevertheless, the multiple in vitro assays that we used
for our study allow to draw the conclusion that hypofrac-
tionated irradiation is one main stimulus for cell death in-
duction and consecutive DC activation in caspase-3
proficient breast cancer cells. Hennel et al. demonstrated
that ablative RT, also as single application, potently in-
duces necrosis in fast proliferating, hormone receptor
negative breast cancer cell lines with mutant p53 [66].
This in turn stimulates monocyte migration and most
likely consecutive immune activation. Therefore, both,
radiation with higher single doses applied in ablative
and hypofractionated RT seem to be a key stimulus for
DC activation by SNs of caspase proficient tumor cells.
Additional immune modulation with HT fosters the
release of higher amounts of Hsp70 and therefore might
result in activation of NK cells. Since synergistic effects
of innate and adaptive immunity are beneficial for the in-
duction of anti-tumor immunity and especially for im-
munological memory [67] it should also be the aim to
activate both CD8+ T cells via DCs and NK cells for ther-
apy of selected breast cancer types. Besides consideration
of disease extent, host factors, patient preferences and so-
cial and economic constraints [68], the configuration of
tumor cells with cell death executing proteins such as
caspases should be included in radio-immunotherapy
decisions to enhance the immunogenicity of distinct
breast cancers by hypofractionated RT alone or in com-
bination with further immune modulation in a person-
alized manner.
Additional file
Additional file 1: Figure S1. MCF-7 and MDA-MB231 breast cancer
cells in the G2 cell cycle phase after hypofractionated irradiation and/or
hyperthermia. MCF-7 (A) or MDA-MB231 (B) tumor cells were treated with
hypofractionated irradiation (4x4Gy or 6x3Gy) and/or hyperthermia (41,5 °C for
1 h). Ionizing irradiation was applied 4 h before or after hyperthermia
on the first and last day of fractionation. 24 h after the last treatment,
the cells were harvested. For determination of the DNA content, the
cells were stained with PI in the presence of detergent and analyzed by
flow cytometry. The percentage of cells in the G2-phase of the cell
cycle is displayed. Representative data of one out of three experiments,
each performed in triplicates, are presented as mean ± SD. Gy: Gray; HT:
hyperthermia; w/o: mock treated control. *p <0,05, **p <0,01 compared
to w/o; # p <0,05, ## p <0,01 compared to only irradiated samples.
(JPEG 359 kb)
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